Veru. has filed a patent for a method of treating coronavirus infections using compounds with anti-tubulin or tubulin disruption activity. The method involves administering a formulation containing a compound of Formula (I) to the infected subject. GlobalData’s report on Veru gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Veru Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Veru, Peptide pharmacophores was a key innovation area identified from patents. Veru's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating coronavirus infections using anti-tubulin compounds

Source: United States Patent and Trademark Office (USPTO). Credit: Veru Inc

A recently filed patent (Publication Number: US20230265081A1) describes a method for treating coronavirus infections using a specific compound. The method involves administering a formulation containing a therapeutically effective amount of a compound of Formula (I) to a subject in need of treatment. The compound is defined by various chemical properties, including the presence of phenyl or indolyl groups that may be substituted with different functional groups. The compound also includes an imidazole group that may be substituted with alkyl groups. The method can be used to treat coronavirus infections in subjects who have or are at high risk of developing acute respiratory distress syndrome (ARDS) or are at high risk of death.

The patent claims that the method reduces viral load and morbidity associated with coronavirus infections. Morbidity refers to various health conditions such as atrial fibrillation, pneumonia, hyperkalemia, hypokalemia, chronic bronchitis, and respiratory failure, among others. The method is specifically designed to treat infections caused by SARS-CoV, MERS-CoV, or SARS-CoV-2, including different variants such as omicron, delta, and their descendants.

The method can be used alone or in combination with other therapies such as remdesivir, dexamethasone, or other corticosteroids. It can also be combined with medications that modulate the immune system or host cell factors, antibody therapies, or other antiviral therapies. Additionally, the method can be combined with vitamins C or D, zinc, famotidine, ivermectin, or angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor binding (ARB) agents.

The compound of Formula (I) is administered in various amounts ranging from about 1 mg to about 100 mg, depending on the specific application. The formulation may also include pharmaceutically acceptable excipients.

Overall, this patent describes a method for treating coronavirus infections using a specific compound, which shows potential for reducing viral load and improving patient outcomes. The method can be used alone or in combination with other therapies, providing a comprehensive approach to treating coronavirus infections.

To know more about GlobalData’s detailed insights on Veru, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies